5 j a n u a r y 2 0 1 7 | V O L 5 4 1 | n a T u r E | 8 7 LETTEr XRCC1 is a molecular scaffold protein that assembles multiprotein complexes involved in DNA single-strand break repair 1,2 . Here we show that biallelic mutations in the human XRCC1 gene are associated with ocular motor apraxia, axonal neuropathy, and progressive cerebellar ataxia. Cells from a patient with mutations in XRCC1 exhibited not only reduced rates of single-strand break repair but also elevated levels of protein ADP-ribosylation. This latter phenotype is recapitulated in a related syndrome caused by mutations in the XRCC1 partner protein PNKP 3-5 and implicates hyperactivation of poly(ADP-ribose) polymerase/s as a cause of cerebellar ataxia. Indeed, remarkably, genetic deletion of Parp1 rescued normal cerebellar ADP-ribose levels and reduced the loss of cerebellar neurons and ataxia in Xrcc1-defective mice, identifying a molecular mechanism by which endogenous single-strand breaks trigger neuropathology. Collectively, these data establish the importance of XRCC1 protein complexes for normal neurological function and identify PARP1 as a therapeutic target in DNA strand break repair-defective disease.
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†Steering committee members and their affiliations appear at the end of the paper. Letter reSeArCH reduced total levels of XRCC1 mRNA were observed in patient-derived cells, as well as aberrant splicing of XRCC1 transcripts if nonsensemediated decay was inhibited with cycloheximide (Extended Data Fig. 1 ).
To establish the pathogenic impact of the biallelic XRCC1 mutations, we examined patient-derived fibroblasts and lymphoblastoid cells (LCLs) for levels of XRCC1 protein by indirect immunofluorescence and western blotting. XRCC1 in patient primary fibroblasts was greatly reduced compared with wild-type (WT) primary human fibroblasts (1BR) by indirect immunofluorescence and was not measurably higher than in human RPE-1 cells in which XRCC1 was deleted by clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 ( Fig. 2a ). However, western blotting suggested that patient fibroblasts Figure 3 | Mutations in patient-derived XRCC1 reduce SSBR. a, DNA strand breaks quantified in the indicated fibroblasts (left) or RPE-1 cells (right) by alkaline comet assays before and at the indicated times after H 2 O 2 treatment. Data are the mean (± s.e.m.) comet tail moments (an arbitrary-unit measure of DNA strand breaks) of three independent experiments. Statistical analyses (two-way analysis of variance) are indicated (* P < 0.05; * * P < 0.01). b, Doublestrand breaks quantified as γ -H2AX foci in the indicated cell lines before and at the indicated times after ionizing radiation (2 Gy). Data are the mean γ -H2AX foci per cell (± 1 s.d.) from three independent experiments (~ 1,000 cells per sample per experiment). Statistical analysis as above. Representative images are in Extended Data Fig. 4 . c, Frequencies of sister chromatid exchange per chromosome (mean ± 1 s.e.m.) quantified in control and XRCC1-patient LCLs (36 metaphases per genotype). Representative metaphases (arrows, sister chromatid exchanges) are shown, left. Statistical analysis, two-tailed t-test (* * P < 0.01; NS, not significant). Scale bars, 10 μ m.
Figure 2
| Mutations in patient-derived XRCC1 reduce XRCC1 levels and recruitment into chromatin. a, XRCC1 levels measured by immunofluorescence in WT 1BR fibroblasts, WT RPE-1 cells, XRCC1-patient fibroblasts, and XRCC1 −/− RPE-1 cells. b, Top: XRCC1 and Lig3α levels measured in the above cells by western blotting and additionally in WT, XRCC1-patient, and sibling LCLs. The source data are included in Supplementary Fig. 1 . Bottom: WT or patient fibroblasts were transfected with non-targeting or XRCC1 siRNA and immunoblotted as above. c, XRCC1 chromatin binding measured by immunofluorescence in the indicated cells before and 10 min after treatment with 1 mM and LCLs both retained a small amount (~ 5%) of residual XRCC1 ( Fig. 2b and Extended Data Fig. 2a ). Indeed, this was confirmed using XRCC1 short interfering RNA (siRNA), which reduced the anti-XRCC1 signal on western blots of patient fibroblasts even further (Fig. 2b, bottom) . Levels of DNA ligase IIIα (Lig3α ) were also greatly reduced (by > 80%) in patient cells, consistent with the established impact of XRCC1 on the cellular stability of this partner protein 6, 7 (Fig. 2b , top, and Extended Data Fig. 2b ). Since germ-line deletion of Xrcc1 in mouse is embryonic lethal 8 , we suggest that the small amount of XRCC1 remaining in the patient was important for embryonic viability. Consistent with this idea, embryonic viability in mice is supported by as little as approximately 10% of normal Xrcc1 levels 9 .
To determine whether the residual XRCC1 in patient cells can engage in single-strand break repair (SSBR), we quantified the extent to which it bound oxidized chromatin. XRCC1 was primarily detected in nucleoli in undamaged WT RPE-1 cells and normal primary 1BR fibroblasts, after the extraction of soluble proteins with detergent, but was rapidly recruited into global nuclear chromatin after treatment with H 2 O 2 (Fig. 2c, d) , a physiological source of oxidative single-strand breaks (SSBs) 10 . By contrast, little or no XRCC1 recruitment into chromatin was detected in XRCC1-patient fibroblasts by high-resolution or high-content imaging (Fig. 2c, d and Extended Data Fig. 3a) . Similar results were observed after treatment with camptothecin (CPT), a topoisomerase poison that induces SSBs triggered by abortive topoisomerase I activity (Extended Data Fig. 3b ). Importantly, the defect in XRCC1 recruitment in patient fibroblasts was accompanied by a delay in the kinetics of DNA SSBR after H 2 O 2 treatment (Fig. 3a ). This phenotype was recapitulated in XRCC1 −/− RPE-1 cells and is consistent with the established molecular role of XRCC1 (ref. 2) . By contrast, we failed to detect a major difference in double-strand break repair in XRCC1-patient fibroblasts, as measured by γ -H2AX immunostaining after ionizing radiation ( Fig. 3b and Extended Data Fig. 4 ). In agreement with the defect in SSBR, XRCC1-patient LCLs exhibited a fourfold increase in sister chromatid exchange, a hyper-recombination phenotype resulting from elevated homologous recombination triggered by unrepaired SSBs in the S/G2 phase of the cell cycle 11 (Fig. 3c ).
XRCC1 is a scaffold protein that assembles SSBR multi-protein complexes. Importantly, components of these complexes are mutated in the cerebellar ataxias spinocerebellar ataxia with axonal neuropathy-1 (SCAN1; mutated in TDP1) 12, 13 , ataxia oculomotor apraxia-1 (AOA1; mutated in aprataxin) 14 , and ataxia oculomotor apraxia-4 (AOA4; mutated in PNKP) 3, 4 . Indeed, it is striking that patients with the XRCC1 mutation combine features of each of these diseases, consistent with the role played by XRCC1 in coordinating their activity. The discovery that XRCC1 is itself mutated in cerebellar ataxia is thus notable because it demonstrates the importance of these complexes in preventing neurodegeneration in humans.
To investigate the mechanism(s) by which unrepaired SSBs trigger neuropathology, we considered the possibility that persistent unrepaired SSBs might result in prolonged activity of the SSB sensor protein PARP1. This hypothesis was prompted by the observation that excessive synthesis of poly(ADP-ribose) and/or excessive depletion of NAD + by PARP1 is neurotoxic and associated with ischaemia reperfusion injury 15, 16 . Consistent with this idea, while ADP-ribose was rapidly detected in both WT and patient fibroblasts after H 2 O 2 treatment, it persisted at a higher level in the latter cells during subsequent incubation in drug-free medium ( Fig. 4a , left). This was also evident in XRCC1 −/− human RPE-1 cells, confirming that this phenotype was induced by loss of XRCC1. Elevated ADP-ribose levels were also detected in XRCC1-patient fibroblasts and XRCC1 −/− RPE-1 cells after treatment with CPT ( Fig. 4a, right) . Indeed, the difference in ADPribose levels between WT and XRCC1-mutant cells was even greater after CPT than after H 2 O 2 treatment. The type of SSB induced by CPT has been linked previously with SSBR-defective neurodegenerative disease and is a possible source of pathogenic SSBs in SSBRdefective individuals 13, 17 . Consistent with this idea, CPT-induced ADP-ribose levels were also elevated in fibroblasts from a patient with ataxia oculomotor apraxia-4 (AOA4); the cerebellar ataxia resulting from mutation of the XRCC1 protein partner, PNKP ( Fig. 4b and Extended Data Fig. 5 ). Importantly, the elevated ADP-ribose observed in CPT-treated XRCC1 −/− RPE-1 cells, XRCC1-patient cells, and PNKP-patient cells was entirely dependent on PARP1 activity ( Fig. 4c and Extended Data Figs 6 and 7). Moreover, this phenotype was rescued by introducing WT recombinant XRCC1 into XRCC1-patient fibroblasts by electroporation ( Fig. 4d and Extended Data Fig. 8 ).
Next, to examine directly whether hyperactive PARP1 triggers cerebellar ataxia in the absence of efficient SSBR, we used a mouse model in which Xrcc1 was conditionally deleted in brain (Xrcc1 Nes-Cre ) 7 . Xrcc1 Nes-Cre mice exhibit pronounced cerebellar histopathology including increased apoptosis of cerebellar granule neurons, greatly reduced numbers of cerebellar interneurons, and decreased electrophysiological spike activity in Purkinje cells (ref. 4 and Extended Data Fig. 9 ). Moreover, consistent with the pathology of the patient with the XRCC1 mutation and other SSBR-defective patients, Xrcc1 Nes-Cre mice exhibit cerebellar ataxia 7 . Strikingly, we detected elevated levels of ADP-ribose in the cerebellum of Xrcc1 Nes-Cre mice, suggesting that the loss of Xrcc1 can trigger Parp1 hyperactivation in the brain even at endogenous levels of SSBs (Fig. 4e ). Indeed, the deletion of Parp1 ablated both the elevated level of ADP-ribose and the characteristic loss of cerebellar interneurons in Xrcc1 Nes-Cre mice, thereby increasing neuronal density in the molecular layer approximately fourfold to WT levels ( Fig. 5a, b ). This did not reflect an impact of Parp1 deletion on the rate of SSBR because the latter was similarly slow in XRCC1 −/− and XRCC1 −/− /PARP1 −/− RPE-1 cells (Extended Data Fig. 10 ). Rather, these data demonstrate that in the absence of Xrcc1-dependent SSBR Parp1 is hyperactivated, resulting in the loss and/or dysfunction of cerebellar neurons. Finally, to examine whether Parp1 deletion also rescued the cerebellar ataxia observed in Xrcc1 Nes-Cre mice, we Indicated are t-test comparisons (* * P < 0.01; * * * P < 0.001). c, Motor coordination in mice of the indicated genotype measured on a rotarod (mouse numbers analysed indicated in/above the bars). Statistical tests as above. d, Model for PARP1 hyperactivation and neural death triggered by unrepaired SSBs. PARP1 activation at SSBs triggers auto-and trans-protein ADP-ribosylation (red wavy lines). XRCC1 binds poly(ADP-ribose) and assembles SSBR protein complexes. Mutated XRCC1 or partner proteins cause delayed SSBR and PARP1 hyperactivation, resulting in cytotoxic levels of poly (ADP-ribose) and/or NAD + depletion. SSBR proteins and their associated cerebellar ataxias are highlighted/boxed in red. SCAN1, spinocerebellar ataxia with axonal neuropathy-1 (TDP1-mutated); AOA1, ataxia oculomotor apraxia-1 (APTX-mutated); AOA4, ataxia oculomotor apraxia-4 (PNKPmutated); AOA-XRCC1, ataxia oculomotor apraxia-XRCC1 mutated 18 . compared Xrcc1 Nes-Cre and Xrcc1 Nes-Cre /Parp1 −/− mice for their performance on an accelerating rotarod. Indeed, remarkably, whereas Xrcc1 Nes-Cre mice were profoundly ataxic and unable to remain on the rotarod for more than a few seconds, the additional deletion of Parp1 improved the rotarod performance of Xrcc1 Nes-Cre mice more than 30-fold, increasing their mean retention time to approximately 30 s (Fig. 5c ).
Collectively, these data identify elevated ADP-ribose levels as a biomarker of PARP1 hyperactivity and as a cause of cerebellar ataxia induced by unrepaired SSBs (Fig. 5d ). This scenario might also extend to other more common neurodegenerative diseases because elevated levels of oxidative stress and DNA strand breakage are also implicated in disorders such as Alzheimer disease, Huntington disease, and Parkinson disease [17] [18] [19] . Intriguingly, patients with mutations in the XRCC1 partner protein PNKP exhibit not only ataxia but also microcephaly and seizures, and we have more recently identified a patient with rare, possibly pathogenic mutations (< 0.01% allele frequency and not present in ExAC in homozygous state) in XRCC1 who exhibits this same combination of phenotypes [3] [4] [5] . Notably, Xrcc1 Nes-Cre mice also present with seizures, raising the prospect that PARP1 hyperactivation may induce not only ataxia, but also more severe pathologies.
Finally, these data identify PARP1 as a possible drug target for treating cerebellar ataxias associated with unrepaired SSBs. Inhibition of PARP1 with currently available chemical inhibitors may not be useful in this context, however, because these inhibitors 'trap' PARP1 on DNA 20 and do not mimic PARP1 genetic deletion (Extended Data Fig. 10 ). However, the development of selective inhibitors of PARP1 that prevent DNA binding by this enzyme may have substantial therapeutic potential.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Whole-exome sequencing. Whole-exome library preparation, exon capture, and sequencing were performed at the Genome Québec Innovation Center (Montréal, QC, Canada) as previously described 19 . Genomic DNA was captured using the SureSelect Human 50Mb All Exon kit v5 (Agilent Technologies, Santa Clara, California, USA). Sequencing was performed on an Illumina HiSeq2000 (Illumina, San Diego, California, USA) with paired-end 100-base-pair (bp) reads. A mean coverage of 137× was obtained and 97% of the bases were covered at more than 10× . Read alignment, variant calling, and annotations were done with a pipeline on the basis of BWA, SAMtools, Annovar, and custom annotation scripts. All sequences were aligned to Human genome Hg19. We excluded variants with minor allele frequency greater than 5% in either the 1000 Genomes Project (http://browser.1000genomes.org/index.html) or the 6500 NHLBI EVS (http://evs.gs.washington.edu/EVS), and seen in more than 30 samples from our in-house database (containing approximately 2,000 samples). The whole-exome sequencing data were further filtered to keep protein-damaging variants (nonsense, missense, frameshift, indel, and splice variants). Antibodies and chemicals. The antibodies used in this study were anti-XRCC1 rabbit polyclonal (Millipore; ABC738), anti-Lig3α (TL25) rabbit polyclonal 20 , anti-PNKP (SK3195) rabbit polyclonal 21 , rabbit Fc-fused Anti-pan-ADP-ribose binding reagent (Millipore; MABE1016), anti-poly(ADP-ribose) rabbit polyclonal (Trevigen; 4336), anti-α -tubulin rat polyclonal (Abcam; ab6160), anti-BrdU rat monoclonal, crossreacting with CldU, (BioRad; OBT0030G), anti-nucleophosmin (B23) mouse monoclonal (Invitrogen; 325200), anti-PARP1 mouse monoclonal (Serotec; MCA1522G), and anti-γ -H2AX mouse monoclonal (Millipore; 05-636). The secondary antibodies used for western blotting were HRP-conjugated goat anti-rabbit (Bio-Rad; 170-6515), goat anti-mouse (Bio-Rad; 170-6516), and rabbit anti-rat (Abcam; ab6734); and for indirect immunofluorescence they were goat anti-mouse or anti-rabbit Alexa 488 (Invitrogen; A11001 and A31628), goat anti-rabbit Alexa 568 (Invitrogen; A11036), donkey anti-mouse Alexa 647 (Invitrogen; A39571), and goat anti-rat Alexa 568 (Invitrogen; A11077). CPT was purchased from Sigma and H 2 O 2 was obtained from Fischer Scientific. Veliparib (ABT-888) was purchased from Selleckchem and KU0058948 hydrochloride from Axon. Cell lines. All cell lines were tested for the absence of mycoplasma. WT human hTERT RPE-1 cells (ATCC; CRL4000) (denoted 'RPE-1' for simplicity) and their XRCC1 −/− derivative (XRCC1 −/− RPE-1 cells) were cultured in Dulbecco's modified Eagle's medium (DMEM/F12; Sigma) supplemented with 10% fetal calf serum and 0.01 mg/ml hygromycin B in a humidified atmosphere of 5% CO 2 at 37 °C. WT control cells were 1BR3 (denoted 1BR in the text for simplicity) primary human fibroblasts and the lymphoblastoid cell line (LCL) 11-27 isolated from a normal, unaffected control. XRCC1-patient primary fibroblasts (identifier number 5596502b) were generated from a patient's skin biopsy and the LCL cell lines HEP15-00082 and HEP15-00083 were obtained from fresh blood from, respectively, the unaffected sibling and affected patient by Epstein-Barr virus transformation. Appropriate patient consent was provided for preparation of primary fibroblasts. Primary human fibroblasts from a PNKP-mutated patient with cerebellar ataxia have been described previously 5 . Primary human fibroblasts were grown in Minimum Essential Media (MEM; Gibco) containing 15% fetal calf serum, 2 mM glutamine, and the antibiotics penicillin (100 units/ml) and streptomycin (100 μ g/ml) at low oxygen (5%) at 37 °C. LCLs were cultured in RPMI medium (Gibco) containing 10% FBS, 2 mM glutamine and penicillin/streptomycin, in a humidified atmosphere of 5% CO 2 at 37 °C. Generation of gene-edited RPE-1 cells. Guide sequences were identified using either E-CRISP (http://www.e-crisp.org/E-CRISP/) or CRISPRdirect (http:// crispr.dbcls.jp). For XRCC1 gene editing we chose the 23-base CRISPR complementary guide RNA sequences 5′ -CCGCCUCCGCCAUGUCGUGUCCU-3′ and 5′ -AGGGACACGACAUGGCGGAGGCGG-3′ (PAM underlined) spanning XRCC1 ORF nucleotides 12-34, and used the 58-base synthetic oligonucleotides (XCr2F; 5 ′ -T TT CT TG GC TT TA TA TA TC TT GT GG AA AG GA CG AA AC AC CGACACGACATGGCGGAGG a nd XCr2R; 5′ -GA CT AG CC TT AT TT TA AC TT GC TA TT TC TA GC TC TA AA AC CCTCCGCCATGTCGTGTC) (Eurofins) encoding 18 bp Tru-guide 22 versions of the guide (underlined) minus the PAM. For PARP1 gene editing we chose the 22-base 'Tru-guide' sequences 5′ -GAAGGUGGGCCACUCCAUCCGG-3′ and 5′ -CCGGAUGGAGUGGCCC ACCUUC-3′ (PAM underlined) spanning nucleotides 174-195 of the human PARP1 ORF, and used the 59-base synthetic oligonucleotides (PARP1-4F: 5 ′ -T TT CT TG G C TT TA TA TA TC TT GT GG AA AG GA CG AA AC AC C GA AGGTGGGCCACTCC ATC-3′ a n d PARP1-4R: 5 ′ -GACTAGCCTTATTTTAACTTGCTATTTCTA GCTCTAAAACGATGGAGTGGCCCACCTTC-3′ ) encoding the 19 bp Tru-guide versions of the guide (underlined) minus the PAM.
The relevant oligonucleotide guide pairs were annealed and extended into a 98-base oligonucleotide duplexes using Phusion polymerase (NEB) and then subcloned into the guide RNA vector (Addgene 41824) 23 using Gibson Assembly (NEB). hTERT RPE-1 cells were co-transfected with the relevant guide construct/s separately (XRCC1 −/− , PARP1 −/− ) or together (XRCC1 −/− /PARP1 −/− ) and with the Cas9 expression construct Addgene 41815 (ref. 23) using a NEON Transfection System (Invitrogen). Twenty-four hours later, the transfected cells were selected in medium containing 0.5 mg/ml G418 for 5 days and subcloned into 96-well plates. Once at sufficient cell density, the subclones were analysed for expression of the relevant protein/s by indirect immunofluorescence. Absence of the relevant protein/s in selected clones was then confirmed by western blotting. For XRCC1 −/− , PARP1 −/− , and XRCC1 −/− /PARP1 −/− RPE-1 cells, we selected clones 3, G7, and D1 for further work, respectively.
Complementation of XRCC1-patient cells with recombinant XRCC1 protein.
Recombinant human XRCC1 harbouring a carboxy (C)-terminal decahisitidine tag (denoted XRCC1-His) was expressed in Escherichia coli from pET16b-XH and purified by metal-chelate affinity chromatography and gel filtration 6 . Control BSA (1 or 2 μ g) or purified XRCC1-His was electroporated into 1 × 10 5 XRCC1-patient fibroblasts using a NEON Transfection System (Invitrogen) according to the manufacturer's protocol. Eighteen hours later the cells were treated with CPT for 45 min, fixed, and immunostained for levels of XRCC1 and ADP-ribose as indicated. RNA extraction, cDNA synthesis, and qPCR analysis. LCLs were treated with either 100 μ g/ml cycloheximide (Sigma) or vehicle alone for 4 h and total RNA extracted with RNAeasy Kit (Qiagen) essentially as described by the manufacturer but with an additional 15 min DNase I (Promega) digest of the samples on the column. 1 μ g total RNA was annealed to oligodT(15) primer and reverse transcribed using M-MuLV RT (NEB) for 2 h at 42 °C. After RNase A digest, the cDNA was purified using PCR purification kit (Qiagen) and 1/40 of the eluate used per reaction. Three replicate qPCR reactions using ABsolute qPCR SYBR Low ROX (Thermo) were performed per experiment in a MX3005P (Agilent) thermocycler and analysed using MxPro software (Agilent). The fold change was calculated from cycle threshold (Δ C t ) values relative to actin and Δ Δ C t values relative to WT untreated for three independent experiments. Primers were as follows: XRCC1 exon10 forward, CAACACCCCCAAGTACAGC; XRCC1 exon 10 reverse, AGTCCAGCACCCACTCCTTAC; XRCC1 exon11 forward, TCCAGCAGTGAGGAGGATG; XRCC1 intron11 reverse, AGGCAAGAGTGGGAAGTTTG; XRCC1 exon 12 reverse, AGTGGGCTTGGTTTTGGTC; actin forward, CTCGTCATACTCCTGCTTGC; actin reverse, GAAGTGTGACGTGGACATCC. XRCC1 cDNA cloning. cDNA prepared as above from patient cells treated with cycloheximide was used for Phusion polymerase (NEB) amplification of full-length XRCC1 transcripts using primers ATGCCGGAGATCCGCCTCCG and GGCTTGCGGCACCACCCCAT. PCR products were purified using Gel extraction kit (Qiagen), cloned using TOPO cloning kit (Thermo Fischer Scientific) and plasmids originating from single colonies purified using Miniprep kit (Qiagen) and sequenced by Sanger sequencing (Beckman Coulter). siRNA. WT and patient primary fibroblasts were reverse-transfected with Lipofectamine RNA iMAX (Life Technologies) as indicated by the manufacturer, using non-targeting siRNA (ON-TARGETplus, Dharmacon) and siXRCC1 SMARTpool (Dharmacon). Western blotting. PBS-washed cells were lysed in Laemmli buffer, heated for 10 min at 95 °C, and sonicated for 30 s using Bioruptor Pico (Diagenode). Protein concentrations were determined using the BCA assay (Pierce). Samples were subjected to SDS-PAGE, proteins transferred onto nitrocellulose membrane and detected by immunoblotting using the relevant primary and horseradish peroxidase-conjugated secondary antibodies. Peroxidase activity was detected by ECL reagent (GE Healthcare) and Amersham Hyperfilm ECL (GE Healthcare). Non-saturated film exposures were digitalized using an EPSONperfection 2400 photo scanner and quantified using ImageJ software. Immunofluorescence and microscopy. Cells cultured on glass coverslips were fixed in 4% paraformaldehyde for 10 min at room temperature, permeabilized in methanol/acetone solution (1:1), blocked in 10% fetal calf serum, and incubated with primary antibodies for 60 min at room temperature. Following rinsing in PBS, coverslips were incubated with secondary antibodies at room temperature for 60 min. Finally, after washing in PBS, nuclei were counterstained with DAPI (Sigma) and coverslips mounted using anti-fading mounting reagent (Vectashield, Vector Laboratories). To measure chromatin retention of proteins, cells were pre-extracted in cold 0.2% Triton X-100 for 2 min on ice before fixation as above. High-resolution microscopy of fixed samples was performed on a Zeiss AxioObserver.Z1 microscope, equipped with oil immersion objectives (Plan-Apochromat 63× /1.4 and 100× /1.4), Hamamatsu ORCA-Flash4.0 LT camera and ZEN 2 core imaging software. Automated wide-field microscopy was performed on an Olympus ScanR system (motorized IX83 microscope) with ScanR Image Acquisition and Analysis Software, 20×/0.45 (LUCPLFLN 20× PH) and 40× /0.6 primers. Both Xrcc1 and Cre PCR products were amplified using the following PCR conditions: initial denaturation for 5 min at 94 °C followed by 35 cycles of 94 °C for 30 s, 59 °C for 45 s and 72 °C for 45 s. Nissl staining of paraffin-embedded sections. Brains were removed at the indicated times and placed in 10% neutral buffered formalin (3.7% formaldehyde, 3.5 g/l NaH 2 PO 4 , 6.5 g/l Na 2 HPO 4 ) for 24 h and then transferred to PBS. Paraffin embedding, sagittal sectioning and Nissl staining were performed by Propath UK (Hereford, UK) and UCL IQPath (Institute of Neurology, London, UK). Briefly, deparaffinized sections were stained in 0.1% cresyl violet solution (0.1% cresyl violet, 0.3% glacial acetic acid) for 3-10 min, rinsed in water, then 95% ethanol for 30 s to 5 min, 100% ethanol for 2 × 5 min, and xylene for 2 × 5 min before mounting. Nissl-positive interneurons were counted within three randomly selected 16,875 μ m 2 regions of each molecular layer, and the number of cells per square micrometre was calculated. Rotarod analysis. To evaluate motor coordination/cerebellar ataxia, an accelerating Panlab Rotarod (Harvard Apparatus, UK) was used. The apparatus was composed of a rod with a diameter of 30 mm divided into five opaque methacrylate arnite barriers, separating the rod into five 50 mm sections. Mice were trained for three successive attempts on the day before assessment. For assessment, mice were positioned on the rod facing away from the experimenter while the rod was stationary. Once activated, the rod accelerated at 0-40 r.p.m. at an acceleration rate of 5 r.p.m. per minute. Mice were rested for 15 min between each of the three trials and then positioned back on the rod for the next assessment. The time spent on the rod was recorded for each mouse and the mean time was calculated from the three independent trials. were not randomized. Samples were not blinded but the collection and analysis of microscopic data were automated and free of user bias. No animals/samples were omitted from data points/data analyses. Data availability. The data sets generated during and/or analysed during the current study are available from the corresponding authors on reasonable request.
(LUCPLFLN 40× PH) dry objectives and Hamamatsu ORCA-R2 digital CCD camera C10600. ADP-ribosylation. Levels of ADP-ribosylation were measured in the indicated cell lines by indirect immunofluorescence using Anti-pan-ADP-ribose binding reagent (Millipore). Cells were treated where indicated with 150 μ M H 2 O 2 for 10 min and then incubated in drug-free medium for 60 min to allow DNA repair or were incubated with 30 μ M CPT for 45 min. ADP-ribose levels were quantified by Olympus ScanR imaging and plotted relative to the ADP-ribose level in untreated cells. For cerebellar sections, postnatal day ((P)17-P23) mice were anaesthetized using 0.2 mg/g Euthanal (Vetoquinol UK) and perfused transcardially with PBS followed by 4% paraformaldehyde. Brains were postfixed in 4% paraformaldehyde for 48 h and stored in 25% sucrose/PBS until moulding and freezing. Sagittal sections (7 μ m) were prepared using a cryostat (Leica CM1850) and immunohistochemistry was conducted essentially as described 7 . Briefly, slides were washed in PBS and heated until boiling in antigen retrieval buffer (Nacalai Tesque, Histo VT One). Endogenous peroxidase was blocked by incubating slides in 0.6% H 2 O 2 in methanol. After incubating in blocking solution (5% goat serum, 1% BSA, 0.4% Triton-X-100 in PBS) rabbit anti-poly(ADP-ribose) primary antibody (Trevigen) was applied overnight. Anti-rabbit Biotin-SP-conjugated AffiniPure Goat secondary antibody (JacksonImmuno Research, 1:500) was incubated on the slides for 1 h followed by ABC reagent (Vectastain Elite ABC kit, Vector Laboratories) according to the manufacturer's instructions. The chromogen was developed using VIP reagent (Vector VIP peroxide substrate kit, Vector Laboratories; SK-4600). Images were obtained using a Nikon Eclipse E400 mounted with Electronic Digital Eyepiece Camera CMOS (C-mount UK). Sister chromatid exchanges. Lymphoblastoid cell lines were incubated in medium containing 8 μ M chlorodeoxyuridine, 32 μ M thymidine, 10 μ M fluorodeoxyuridine, and 200 μ M cytidine (such that 20% of incorporated thymidine was replaced with chlorodeoxyuridine) 11, 24 for 20 h, washed twice in media, and then allowed to grow for another 20 h in medium containing 10 μ M thymidine. Cells were treated with 100 ng/ml colcemid for 1 h, swollen in 75 mM KCl for 5 min at 37 °C, and fixed in Carnoy's fixative before preparation of metaphase spreads. Slides were allowed to dry in air, rehydrated in PBS, incubated in 2 M HCl for 30 min, washed twice in 100 mM borate buffer pH 8.5 for 10 min, and blocked in 10% fetal calf serum in PBS for 30 min. Further immunofluorescence and imaging was performed as above. Single-and double-strand break assays. Alkaline comet assays were performed essentially as described 25 and DNA breaks induced with 50 μ M H 2 O 2 (RPE-1 cells) or 25 μ M H 2 O 2 (primary fibroblasts) for 10 min on ice. Data are plotted as the average comet tail moment (an arbitrary-unit measure of DNA strand breaks) of 100 cells per sample and are the mean (± s.e.m.) of three independent experiments. For double-strand break repair assays, cells were irradiated with 2 Gy using a Gammacell 1000 machine, and γ -H2AX quantified at the indicated times, afterwards. Data are the average number of γ -H2AX foci per cell from about 1,000 cells per sample, scored by Olympus ScanR software, and are the mean (± 1 s.d.) of three independent experiments. Mouse maintenance and analysis. Animals were maintained and used under the auspices of UK Home Office project licence number 70/8300. The generation of Parp1 −/− and Xrcc1 Nes-Cre mice have been reported previously 7, 26 . Intercrosses between Parp1 −/− and Xrcc1 +/loxp mice were maintained in a mixed C57/Bl6 × S129 strain and housed on a 12 h light/dark cycle with lights on at 7:00. Temperature and humidity were maintained at 21 °C (± 2 °C) and 50% (± 10%), respectively. All experiments were performed under the UK Animal (Experimental Procedures) Act, 1986. Genomic DNA was extracted from biopsied tail using the REDExtract-N-Amp Tissue PCR Kit in accordance to the manufacturer's instructions (Sigma). For Parp1, the following primers were used: Parp1 F1 (5′ -GTT GTG AAC GAC CTT CTG GG-3′ ), Parp1 R1 (5′ -CCT TCC AGA AGC AGG AGA AG-3′ ), and Parp1 R2 (5′ -GCT TCA GTG ACA ACG TCG AG-3′ ). PCR products were generated by an initial denaturation step at 94 °C for 2 min followed by 35 cycles of 94 °C for 30 s, 54 °C for 40 s, and 72 °C for 180 s. Xrcc1 was amplified using the forward PC1 (5′ -TAT GCT TGC TGT ACA GGG ATT GGG-3′ ) and reverse PC2 (5′ -TGG ACC ATG AAA AAG CTG TGT GC-3′ ) primers. A 400 bp cre PCR product was generated using the forward Cre-3 (5′ -CTG CCA CGA CCA AGT GAC AGC-3′ ) and reverse Cre-4 (5′ -ACC TGC GGT GCT AAC CAG CG-3′ )
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Extended Data Figure 1 | Aberrant splicing of XRCC1 pre-mRNA in XRCC1-patient cells. a, qPCR analysis of cDNA prepared from polyAtailed RNA from WT, unaffected sibling, and patient LCLs. Cells were mock-treated or treated with cycloheximide (CHX) to inhibit nonsensemediated decay. Cartoons show the position of primers used to quantify total XRCC1 mRNA (left), mRNA with correctly spliced exon11/12 junction (middle), or intron 11 retention (right). Fold change was calculated from Δ Δ C t values relative to actin and untreated WT from three independent experiments (mean ± s.e.m.). b, Summary of splicing defects observed in sequenced XRCC1 transcripts from sibling and patient cells treated with CHX. Whole XRCC1 cDNA was amplified from oligodTprimed reverse-transcribed RNA and individual transcripts cloned and sequenced. The allelic origin of individual patient transcripts was assigned using a R399Q SNP in the Q465X allele.
Extended Data Figure 5 | Elevated ADP-ribosylation in XRCC1 −/− RPE-1 cells, XRCC1-patient fibroblasts, and PNKP-patient fibroblasts. a, ADP-ribosylated proteins were detected in cell extracts from WT RPE-1 cells, XRCC1 −/− RPE-1 cells, WT 1BR fibroblasts, XRCC1-patient fibroblasts ('X1 patient'), and PNKP-patient fibroblasts treated as in Fig. 4a by western blotting and Anti-pan-ADP-ribose binding reagent. b, Levels of ADP-ribosylation in 1BR WT, XRCC1-patient, and PNKPpatient fibroblasts measured before and after CPT treatment by indirect immunofluorescence as indicated in Fig. 4b . Representative ScanR images are shown.
